Cidara Therapeutics Company Profile (NASDAQ:CDTX)

About Cidara Therapeutics

Cidara Therapeutics logoCidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CDTX
  • CUSIP:
Key Metrics:
  • Previous Close: $10.97
  • 50 Day Moving Average: $11.61
  • 200 Day Moving Average: $11.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.30
  • P/E Growth: 0.00
  • Market Cap: $152.55M
  • Outstanding Shares: 13,906,000
  • Beta: 2.24
Additional Links:
Companies Related to Cidara Therapeutics:

Analyst Ratings

Consensus Ratings for Cidara Therapeutics (NASDAQ:CDTX) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $19.75 (80.04% upside)

Analysts' Ratings History for Cidara Therapeutics (NASDAQ:CDTX)
Show:
DateFirmActionRatingPrice TargetDetails
8/16/2016WedbushReiterated RatingOutperformView Rating Details
8/15/2016BTIG ResearchReiterated RatingBuy$24.00View Rating Details
8/15/2016Needham & Company LLCReiterated RatingBuy$20.00View Rating Details
6/12/2016Leerink SwannReiterated RatingBuyView Rating Details
5/14/2016Jefferies GroupReiterated RatingBuyView Rating Details
10/9/2015WBB SecuritiesUpgradeSell -> Hold$13.00View Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Cidara Therapeutics (NASDAQ:CDTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016        
8/11/2016Q2($0.76)($0.85)ViewN/AView Earnings Details
5/12/2016Q1($0.76)($0.71)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cidara Therapeutics (NASDAQ:CDTX)
Current Year EPS Consensus Estimate: $-3.37 EPS
Next Year EPS Consensus Estimate: $-3.32 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.82)($0.75)($0.78)
Q2 20163($0.85)($0.77)($0.80)
Q3 20163($0.90)($0.82)($0.86)
Q4 20163($0.95)($0.85)($0.89)
Q1 20171($0.89)($0.89)($0.89)
Q2 20171($0.74)($0.74)($0.74)
Q3 20171($0.75)($0.75)($0.75)
Q4 20171($0.76)($0.76)($0.76)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cidara Therapeutics (NASDAQ:CDTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cidara Therapeutics (NASDAQ:CDTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/20/2016Jeffrey SteinCEOBuy4,310$11.51$49,608.10View SEC Filing  
5/20/2016Kevin ForrestCFOBuy4,356$11.53$50,224.68View SEC Filing  
11/25/2015Jeffrey SteinCEOBuy6,700$15.09$101,103.00View SEC Filing  
11/23/2015Kevin ForrestCFOBuy7,087$14.23$100,848.01View SEC Filing  
4/20/2015Timothy R FransonDirectorBuy4,000$16.00$64,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cidara Therapeutics (NASDAQ:CDTX)
DateHeadline
globenewswire.com logoCidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:CDTX)
globenewswire.com - August 11 at 9:58 PM
sg.finance.yahoo.com logoCidara Therapeutics reports 2Q loss (NASDAQ:CDTX)
sg.finance.yahoo.com - August 11 at 9:58 PM
publicnow.com logoCidara Therapeutics Announces Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting (NASDAQ:CDTX)
www.publicnow.com - August 9 at 12:46 PM
publicnow.com logoCidara Therapeutics to Present at the Cantor Fitzgerald Annual Healthcare Conference (NASDAQ:CDTX)
www.publicnow.com - July 6 at 7:11 AM
publicnow.com logoCidara Therapeutics Expands Management Team (NASDAQ:CDTX)
www.publicnow.com - July 5 at 7:21 AM
biz.yahoo.com logoCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:CDTX)
biz.yahoo.com - June 24 at 4:06 PM
seekingalpha.com logoThe Market Is Ignoring The Potential Of Scynexis' SCY-098 In Invasive Fungal Infections (NASDAQ:CDTX)
seekingalpha.com - June 22 at 4:16 PM
fxpips.com logopSivida (PSDV), The ONE (STKS), Trinity Place (TPHS), Cidara (CDTX) Post Gaps Up today (NASDAQ:CDTX)
www.fxpips.com - June 22 at 8:51 AM
streetinsider.com logoCidara Therapeutics (CDTX) Doses First Patient in Phase 2 Trial of CD101 Topical to Treat VVC (NASDAQ:CDTX)
www.streetinsider.com - June 10 at 4:11 PM
publicnow.com logoCidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis (NASDAQ:CDTX)
www.publicnow.com - June 9 at 7:39 AM
publicnow.com logoCidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 (NASDAQ:CDTX)
www.publicnow.com - June 8 at 7:48 AM
capitalcube.com logoCidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 (NASDAQ:CDTX)
www.capitalcube.com - June 6 at 2:31 PM
benzinga.com logoCDTX: Insiders vs. Shorts (NASDAQ:CDTX)
www.benzinga.com - June 2 at 12:54 PM
publicnow.com logoCidara Therapeutics to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:CDTX)
www.publicnow.com - June 2 at 8:15 AM
streetinsider.com logoCidara Therapeutics (CDTX) Granted FDA Fast Track Status for CD101 Topical (NASDAQ:CDTX)
www.streetinsider.com - June 1 at 10:15 PM
publicnow.com logoFDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics’ Novel Antifungal Product Candidate (NASDAQ:CDTX)
www.publicnow.com - May 31 at 7:52 AM
finance.yahoo.com logoCIDARA THERAPEUTICS, INC. Financials (NASDAQ:CDTX)
finance.yahoo.com - May 20 at 1:04 PM
biz.yahoo.com logoCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex (NASDAQ:CDTX)
biz.yahoo.com - May 20 at 6:05 AM
publicnow.com logoCidara Reports First Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:CDTX)
www.publicnow.com - May 12 at 5:27 PM
publicnow.com logoCidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016 (NASDAQ:CDTX)
www.publicnow.com - April 6 at 7:19 AM
publicnow.com logoCidara Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference (NASDAQ:CDTX)
www.publicnow.com - April 5 at 8:00 AM
sg.finance.yahoo.com logoCidara Therapeutics reports 4Q loss (NASDAQ:CDTX)
sg.finance.yahoo.com - March 18 at 7:43 AM
finance.yahoo.com logoCidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update (NASDAQ:CDTX)
finance.yahoo.com - March 18 at 7:30 AM
finance.yahoo.com logoA Potential Answer To Antibiotic Resistance (NASDAQ:CDTX)
finance.yahoo.com - March 7 at 1:22 PM
thestreet.com logoAnalysts Forecast 35% Upside For VTWG (NASDAQ:CDTX)
www.thestreet.com - February 25 at 2:38 PM
4-traders.com logoCidara Therapeutics : Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis (NASDAQ:CDTX)
www.4-traders.com - February 18 at 2:20 PM
thestreet.com logoCIDARA RECEIVES ORPHAN DRUG DESIGNATION FOR NOVEL ECHINOCANDIN, CD101 IV, IN CANDIDEMIA AND INVASIVE CANDIDIASIS (NASDAQ:CDTX)
www.thestreet.com - February 11 at 2:23 PM
tmcnet.com logoCidara Receives Orphan Drug Designation for Novel Echinocandin, CU101 IV, in Candidemia and Invasive Candidiasis (NASDAQ:CDTX)
www.tmcnet.com - February 10 at 1:57 PM
finance.yahoo.com logoCORRECTING and REPLACING Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis (NASDAQ:CDTX)
finance.yahoo.com - February 10 at 7:40 AM
finance.yahoo.com logo7:01 am Cidara Therapeutics confirms that the FDA has granted orphan drug designation to its antifungal drug candidate, CD101 IV, for the treatment of candidemia and invasive candidiasis (NASDAQ:CDTX)
finance.yahoo.com - February 10 at 7:01 AM
finance.yahoo.com logoCidara Therapeutics Announces Participation in Leerink Partners 5th Annual Global Healthcare Conference (NASDAQ:CDTX)
finance.yahoo.com - February 3 at 7:30 AM
noodls.com logoCidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV (NASDAQ:CDTX)
www.noodls.com - January 11 at 9:18 AM
noodls.com logoCidara Therapeutics Commends IDSA for New Candidiasis Clinical Management Guidelines (NASDAQ:CDTX)
www.noodls.com - December 21 at 9:26 AM
insidermonkey.com logoShould You Avoid Mattson Technology, Inc. (MTSN)? (NASDAQ:CDTX)
www.insidermonkey.com - December 7 at 1:44 PM
finance.yahoo.com logoWhat's the Market Data Pointing At - Research on Cidara, Alpha and Omega, Park City Group and CRA International (NASDAQ:CDTX)
finance.yahoo.com - December 7 at 7:50 AM
insidermonkey.com logoCidara Therapeutics Inc (CDTX): Are Hedge Funds Right About This Stock? (NASDAQ:CDTX)
www.insidermonkey.com - November 29 at 6:14 PM
finance.yahoo.com logoNew Information Reveals Opportunity in Volatility - Research on Cidara Therapeutics, Alpha and Omega Semiconductor, Park City Group and CRA International (NASDAQ:CDTX)
finance.yahoo.com - November 27 at 8:40 AM
noodls.com logoCidara Therapeutics Announces Positive Data From Phase 1 Clinical Trial of CD101 IV and Reports Third Quarter 2015 Financial Results (NASDAQ:CDTX)
www.noodls.com - November 16 at 4:34 PM
biz.yahoo.com logoCIDARA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:CDTX)
biz.yahoo.com - November 16 at 4:02 PM
biz.yahoo.com logoCidara Therapeutics Inc Earnings Call scheduled for 8:00 am ET today (NASDAQ:CDTX)
biz.yahoo.com - November 16 at 8:00 AM
noodls.com logoCidara Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference in London (NASDAQ:CDTX)
www.noodls.com - November 10 at 7:56 AM

Social

Cidara Therapeutics (NASDAQ:CDTX) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff